Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Pain relief typically kicked in within two to four hours, according to Vertex, and VX-540 was also associated with manageable side effects, mainly minor complaints like nausea, headache ...

The first medical treatment to use Crispr gene editing has been on the market for a year. Its complexity means few patients ...

Jefferies upgraded Vertex to Buy from Hold following improved fundamentals and a growing pipeline worth $5 billion-7 billion, which includes treatments for chronic pain and APOL1 kidney disease.

BMO Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $566 but keeps an Outperform rating on the shares.